TransCode Therapeutics, Inc. (RNAZ)
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
$4.50M
Mr. Robert Michael Dudley
8.00
Boston, MA
Apr 28, 2021
0.00
$268.14
1.01
1.39
0.00%
-0.00
0.15
0.00
1.01
-530.28%
-935.16%
Similar stocks (13)
Kodiak Sciences Inc.
KOD
Immix Biopharma, Inc.
IMMX
Eyenovia, Inc.
EYEN
Cognition Therapeutics, Inc.
CGTX
Xenetic Biosciences, Inc.
XBIO
CNS Pharmaceuticals, Inc.
CNSP
Sonnet BioTherapeutics Holdings, Inc.
SONN
Phio Pharmaceuticals Corp.
PHIO
ZyVersa Therapeutics, Inc.
ZVSA
Revelation Biosciences, Inc.
REVB
NexImmune, Inc.
NEXI
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
Similar stocks (13)
Kodiak Sciences Inc.
KOD
Immix Biopharma, Inc.
IMMX
Eyenovia, Inc.
EYEN
Cognition Therapeutics, Inc.
CGTX
Xenetic Biosciences, Inc.
XBIO
CNS Pharmaceuticals, Inc.
CNSP
Sonnet BioTherapeutics Holdings, Inc.
SONN
Phio Pharmaceuticals Corp.
PHIO
ZyVersa Therapeutics, Inc.
ZVSA
Revelation Biosciences, Inc.
REVB
NexImmune, Inc.
NEXI
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB